Assyro AI

FDA Orange Book · active-ingredient family

Palonosetron hydrochloride

Palonosetron hydrochloride is approved as 5 brand and 18 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.

5

Brand (NDA)

18

Generics (ANDA)

0

Listed patents

0

Exclusivity periods

Brand (NDA) products · capsule, injectable, solution

ProductApplicantApplicationTEApproved
PALONOSETRON HYDROCHLORIDERLDFRESENIUS KABI USANDA 208109Nov 21, 2017
POSFREARLD×2AVYXA HOLDINGSNDA 203050Mar 01, 2016
ALOXIRLDHELSINN HLTHCARENDA 022233Aug 22, 2008
ALOXIRLD×2HELSINN HLTHCARENDA 021372Feb 29, 2008
PALONOSETRON HYDROCHLORIDEHIKMANDA 207963Aug 22, 2016

Generic (ANDA) products (18)

ProductApplicantApplicationTEApproved
PALONOSETRON HYDROCHLORIDEMEITHEALANDA 215861APAug 14, 2023
PALONOSETRON HYDROCHLORIDEBAXTER HLTHCARE CORPANDA 206916APNov 12, 2021
PALONOSETRON HYDROCHLORIDE×2AVET LIFESCIENCESANDA 202951Jun 29, 2021
PALONOSETRON HYDROCHLORIDEACCORD HLTHCAREANDA 204615Mar 15, 2021
PALONOSETRON HYDROCHLORIDEINGENUS PHARMS LLCANDA 208789May 22, 2020
PALONOSETRON HYDROCHLORIDEEUGIA PHARMAANDA 204702APNov 06, 2018
PALONOSETRON HYDROCHLORIDECHARTWELL RXANDA 209287APSep 19, 2018
PALONOSETRON HYDROCHLORIDECIPLAANDA 206396Sep 19, 2018
PALONOSETRON HYDROCHLORIDEFRESENIUS KABI USAANDA 206801APSep 19, 2018
PALONOSETRON HYDROCHLORIDEFRESENIUS KABI USAANDA 206802APSep 19, 2018
PALONOSETRON HYDROCHLORIDE×2HOSPIRAANDA 207005APSep 19, 2018
PALONOSETRON HYDROCHLORIDEMYLAN INSTITUTIONALANDA 206416APSep 19, 2018
PALONOSETRON HYDROCHLORIDE×2QILU PHARM HAINANANDA 205648Sep 19, 2018
PALONOSETRON HYDROCHLORIDESAGENT PHARMS INCANDA 204289APSep 19, 2018
PALONOSETRON HYDROCHLORIDESAGENT PHARMS INCANDA 205870APSep 19, 2018
PALONOSETRON HYDROCHLORIDE×2TEVA PHARMS USAANDA 090713Mar 23, 2018
PALONOSETRON HYDROCHLORIDE×2DR REDDYSANDA 201533Apr 21, 2016
PALONOSETRON HYDROCHLORIDESANDOZANDA 202521APOct 13, 2015

Listed patents

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Palonosetron hydrochloride — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.